Dogs develop tumors spontaneously

Our Efficacy Model for Cancer Research uses affected companion dogs looking for a better cancer treatment to evaluate the efficacy of new compounds

Translated Research Models:

1. Dose, PK and PD data

New chemotherapy agent, target therapy and immunotherapy can be used in this platform. After mice study we can plan a Phase I Companion Animal Clinical trial and have toxicity, pharmacokinetic (PK) and pharmacodynamic (PD) information.

2. Efficacy data

We can design clinical trials in companion animals selecting a subgroup of dogs with specific clinical staying, histology and molecular subtype.

Clinical Staging

Early or late disease stage

Histology 

You can evaluate the efficacy of your compound for specific histology type according to your compound activity, you can also determined the grading of the tumor to study.

Molecular Subtype

Molecular classification of tumors can be performed for target therapy and for a better characterization of the tumor. 

Canine mammary tumors are not common in United States due to dog's early spay, Ridge Research developed an international recruitment sites to be able to enroll a high number of affected dogs. Canine mammary gland carcinoma is a well-known animal model for human breast cancer and can be used to get data for you compound helping to design human clinical trials.  

Tumors are developed in dogs spontaneously without chemical or genetic induce, and there are close similarities between molecular, anatomic clinical features comparing human breast cancer and canine mammary tumors. Dogs share the same environment as humans with highly comparable nutritional needs, and naturally develop various cancers with a shorter natural history.

  • age and disease development

  • hormonal etiology

  • identical course of the disease

  • Important facts that affect the clinical outcome: tumor size, clinical stage, lymph node infiltration and lung metastasis

  • Histology similarities

    • Molecular characteristics: steroid receptor, epidermal growth factor (EGF), proliferation markers, metalloproteinase, COX-2, p53

    • Similar immunoresponse: similar tumor inflammatory cells in the tumor

Clinical trials in companion animals is a go/no-go decision. Is much more reliable compared to mouse model. You can save money and move to phase I  human clinical trial a compound with a higher chance to work.

Phase I

Goals:

- Determine maximally tolerated dose

- Define dose limiting toxicity

- PK and PD information

- Preliminary efficacy data

Trial Characteristics:

- Single-Institution trials

- 9 - 21 dogs with spontaneous tumors

- Fast enrollment and results

Phase II

Goals:

- Determine the activity and efficacy in a define population

- Estimated therapeutic index

- Expand toxicity data

- Evaluate additional dosing groups

- Quality of life measures 

Trial Characteristics:

- Multi-Institution trials

- Number of dogs depending on study design

Tumor Models:

- Oral melanoma

- Lymphoma

- Breast cancer

- Bladder tumor

- Soft tissue sarcoma

- Osteosarcoma

Phase III

Goals:

- Compare efficacy of a new drug or combination to current standard treatment

Trial Characteristics:

- Multi-Institution trials

- Number of dogs depending on study design

Tumor Models:

- Oral melanoma

- Lymphoma

- Breast cancer

- Bladder tumor

- Soft tissue sarcoma

- Osteosarcoma

SIMPLY FILL OUT THE FOLLOWING FORM AND WE’LL BE IN TOUCH SHORTLY
Business Type
Type of Study

© RIDGE RESEARCH 2016-2019